Project UpdateMay 13, 2026, 02:07 AM
Aligos to present 10 abstracts on HBV, MASH programs at EASL 2026
AI Summary
Aligos Therapeutics announced that ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026. These presentations will detail progress on several of the company's drug candidates, including pevifoscorvir sodium and ALG-170675 for chronic hepatitis B (HBV), and ALG-055009 for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company will also present preclinical data on hepatitis delta virus (HDV) infections and a PD-1/PD-L1 inhibitor for HBV and liver cancer. The congress is scheduled from May 27-30, 2026, in Barcelona, Spain.
Key Highlights
- 10 abstracts accepted for poster presentations at EASL Congress 2026.
- Presentations on pevifoscorvir sodium (CAM-E) for chronic HBV infection.
- Presentations on ALG-170675 (ASO) for chronic HBV infection.
- Presentation on ALG-055009 (THR-β Agonist) for MASH.
- Preclinical data on hepatitis delta virus (HDV) infections.
- Preclinical data on ALG-093940, a PD-1/PD-L1 inhibitor for HBV and liver cancer.
- EASL Congress 2026 to be held May 27-30, 2026, in Barcelona, Spain.
Price Impact
More from ALGS